The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

Drug Intelligence & Clinical Pharmacy: Vol. 22, No. 11, pp. 843-849.
© 1988 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Woloschuk, D.
Right arrow Articles by Cluxton RJ,
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Woloschuk, D.
Right arrow Articles by Cluxton RJ, , Jr

Research Articles

Carboplatin: a new cisplatin analog

DM Woloschuk, JM Pruemer, and Cluxton RJ Jr

Carboplatin, a new antineoplastic agent with a spectrum of antitumor activity similar to cisplatin, has shown appreciable activity in patients with ovarian carcinoma, head and neck cancer, and small-cell lung cancer. This platinum complex is less nephrotoxic, ototoxic, and neurotoxic than cisplatin. Myelosuppression may be severe and dose-limiting. Carboplatin distributes into a volume approximating total body water, and is slowly bound to plasma proteins; its elimination is a biphasic process. Renal clearance of free platinum from carboplatin correlates highly with creatinine clearance in patients with normal or impaired renal function. The recommended iv dose of carboplatin as a single agent in previously untreated patients is 400-500 mg/m2; dosage must be reduced in patients with decreased renal function, low initial platelet count, or extensive prior chemotherapy or radiation therapy. Carboplatin will be most useful in patients with decreased renal function and those who cannot tolerate high-volume hydration regimens. Patients at higher risk for development of cisplatin-related ototoxicity or neurotoxicity (e.g., patients expected to receive cumulative cisplatin doses exceeding 600-800 mg/m2) may be ideal candidates for carboplatin as initial therapy. Large-scale comparative trials are needed before carboplatin can be recommended as a replacement for cisplatin.


This article has been cited by other articles:


Home page
 Exp. Biol. Med.Home page
T. M. Krupka, B. D. Weinberg, H. Wu, N. P. Ziats, and A. A. Exner
Effect of Intratumoral Injection of Carboplatin Combined with Pluronic P85 or L61 on Experimental Colorectal Carcinoma in Rats
Experimental Biology and Medicine, July 1, 2007; 232(7): 950 - 957.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
J. M. Scholtz
General Principles and Pharmacology of Antineoplastic Agents
Journal of Pharmacy Practice, January 1, 1991; 4(1): 3 - 10.
[PDF]

Home page
 Journal of Pharmacy PracticeHome page
L. E. Davis
Long-Term Complications of Antineoplastic Agents
Journal of Pharmacy Practice, January 1, 1991; 4(2): 131 - 150.
[PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1988 by Harvey Whitney Books Company.